vs
Side-by-side financial comparison of International General Insurance Holdings Ltd. (IGIC) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $403.8M, roughly 1.9× International General Insurance Holdings Ltd.). International General Insurance Holdings Ltd. runs the higher net margin — 26.0% vs 13.0%, a 13.1% gap on every dollar of revenue.
China Taiping Insurance Holdings Company Limited (CTIH) formerly China Insurance International Holdings Company Limited (CIIH), is a Chinese insurance conglomerate. The company has strong Chinese Central Government background despite being incorporated in Hong Kong. It is considered as a red chip company.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
IGIC vs PODD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $403.8M | $783.7M |
| Net Profit | $105.1M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 26.0% | 13.0% |
| Revenue YoY | — | 31.2% |
| Net Profit YoY | — | 0.9% |
| EPS (diluted) | $2.31 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $783.7M | ||
| Q3 25 | $403.8M | $706.3M | ||
| Q2 25 | $261.9M | $649.1M | ||
| Q1 25 | — | $569.0M | ||
| Q4 24 | — | $597.5M | ||
| Q3 24 | $369.6M | $543.9M | ||
| Q2 24 | $265.8M | $488.5M | ||
| Q1 24 | — | $441.7M |
| Q4 25 | — | $101.6M | ||
| Q3 25 | $105.1M | $87.6M | ||
| Q2 25 | $61.4M | $22.5M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | — | $100.7M | ||
| Q3 24 | $-134.4M | $77.5M | ||
| Q2 24 | $70.7M | $188.6M | ||
| Q1 24 | — | $51.5M |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% | ||
| Q1 24 | — | 69.5% |
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | 24.2% | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | -73.3% | 11.2% | ||
| Q1 24 | — | 12.9% |
| Q4 25 | — | 13.0% | ||
| Q3 25 | 26.0% | 12.4% | ||
| Q2 25 | 23.5% | 3.5% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | -36.4% | 14.2% | ||
| Q2 24 | 26.6% | 38.6% | ||
| Q1 24 | — | 11.7% |
| Q4 25 | — | $1.42 | ||
| Q3 25 | $2.31 | $1.24 | ||
| Q2 25 | $1.36 | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | — | $1.38 | ||
| Q3 24 | $1.82 | $1.08 | ||
| Q2 24 | $1.55 | $2.59 | ||
| Q1 24 | — | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $244.7M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $654.8M | $1.5B |
| Total Assets | $2.0B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $244.7M | — | ||
| Q2 25 | $164.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $219.2M | — | ||
| Q2 24 | $237.3M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $654.8M | $1.4B | ||
| Q2 25 | $662.3M | $1.5B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $540.5M | $1.1B | ||
| Q2 24 | $588.2M | $998.4M | ||
| Q1 24 | — | $790.7M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | $2.0B | $3.0B | ||
| Q2 25 | $2.1B | $3.5B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | $1.8B | $3.0B | ||
| Q2 24 | $2.0B | $2.9B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $183.3M | ||
| Q3 25 | — | $125.7M | ||
| Q2 25 | $27.2M | $196.5M | ||
| Q1 25 | — | $63.8M | ||
| Q4 24 | — | $147.7M | ||
| Q3 24 | — | $98.5M | ||
| Q2 24 | $120.7M | $96.5M | ||
| Q1 24 | — | $87.6M |
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | $26.8M | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | $119.8M | $74.0M | ||
| Q1 24 | — | $65.5M |
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | 10.2% | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | 45.1% | 15.1% | ||
| Q1 24 | — | 14.8% |
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | 0.2% | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | 0.3% | 4.6% | ||
| Q1 24 | — | 5.0% |
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 0.44× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 1.71× | 0.51× | ||
| Q1 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IGIC
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
